To order this detailed 290+ page report, please visit this link
Key Inclusions
- A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
- Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
- Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
- A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
- An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
- A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
- A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
- An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
- A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
- Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
- A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
- A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
- Key Drug Discovery Steps
- Target Identification
- Target Validation
- Hit Generation
- Hit-to-Lead
- Lead Optimization
- Type of Large Molecule
- Antibodies
- Proteins
- Peptides
- Nucleic Acids
- Vectors
- Company Size
- Small
- Mid-sized
- Large
- Target therapeutic Area
- Autoimmune Disorders
- Blood Disorders
- Cardiovascular Disorders
- Gastrointestinal and Digestive Disorders
- Hormonal Disorders
- Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
- Infectious Diseases
- Metabolic Disorders
- Mental Disorders
- Musculoskeletal Disorders
- Neurological Disorders
- Oncological Disorders
- Respiratory Disorders
- Skin Disorders
- Urogenital Disorders
- Others
- Type of Sponsor
- Industry Players
- Non-Industry Players
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
The report includes detailed transcripts of discussions held with the following experts:
- John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
- Sven Benson (Founder, candidum)
- Mark Whittaker (Senior Vice President, Evotec)
- Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)
To request sample pages, please visit this link
Key Questions Answered
- Who are the leading in silico service providers for discovery of different types of large molecule drugs?
- What are the key challenges associated with the discovery of large molecule drugs?
- What is the likely cost saving opportunity associated with the use of in silico tools?
- What are the key computational approaches being used by in silico service providers for drug discovery operations?
- What are the popular business strategies being used by in silico drug discovery service providers?
- How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
- DNA-Encoded Libraries: Platforms and Services Market
- Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
- Companion Diagnostics Services Market, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
Human factors engineering and usability testing have now become an essential part of product design across almost all industries, offering developers the chance to optimize proprietary products in alignment to the preferences of consumers London Roots Analysis has announced the addition of “Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030” report to its list of offerings.
Moreover, as such solutions are gradually becoming increasingly complex, it is imperative to identify potential risks / hazards, in order to guarantee safety to end users post product launch.
However, the aforementioned processes require specialized resources and expertise.
Therefore, outsourcing this aspect of product design and development, has become common among industry stakeholders.
To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this link Key Market Insights Around 105 companies / organizations claim to be engaged in offering human factors engineering and usability testing services for medical devicesIt is worth noting that this market is currently dominated by the presence of small players (2 to 50 employees), which represent more than 67% of the players.
Majority (57%) of the players engaged in this domain offer services for hospital / laboratory equipment and instruments Various companies (53%) engaged in this domain claim to offer human factors engineering and usability testing services for diagnostic devices, followed by those providing support for drug delivery devices (44%), home use medical devices (36%), clinical use devices (26%) and therapeutic devices (25%).
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment London Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.
Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.
Europe is currently regarded as a key manufacturing hub for microbial biologicsThere are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%).
On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.
Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).
A product launch is not an easy task by any stretch of the imagination as it involves multiple groups working as a team to churn out the desired results.
Your company might have launched several drugs before but that would not have a huge say in your new venture going smooth.Failures can occur but the key here is to not worry about them and instead learn from them.
We often talk about the success mantras but rarely do we talk about the mistakes that you need to avoid during a product launch.So, here we have listed the three mistakes that you need to definitely avoid while preparing a drug launch.Not thinking about the big pictureOne of the biggest mistakes that you can make is to not think about the big picture right from the beginning.
When it comes to a drug launch, there are innumerable things to keep in mind, like, licensing, target audience, business campaign, marketing strategy, manufacturing speed, product-pitching, and so on.One way to go about the whole process is to focus on just the specific aspects that you feel need the most attention and forget about the rest of the things.
Yes, this can deliver faster results but it can backfire in a huge way in some cases.
Even the smallest of mistakes in neglected areas can jeopardize the whole product launch.Therefore, the right way to go about it is to first identify all the steps involved in the process of product launch and then go through it one-by-one.
Global Research Antibodies Market size is expected to reach USD 4.30 billion by 2025.
Antibodies are secreted immunoglobin molecules mainly produced by plasma cells.
The market size is expected to expand at a CAGR of 6.1% in the upcoming period.In research antibodies, some technologies are used such as Immunohistochemistry, Western Blotting, Immunofluorescence, Immunoprecipitation, Flow Cytometry, ELISA, and others.
The “western blotting” segment held largest market share in 2016 and is expected to hold the highest market share in the upcoming period due to growing prevalence of diseases with limited treatment options such as HIV.
The segment is anticipated to grow at the highest CAGR during the forecast period owing to the increasing adoption of reagents containing primary research antibodies due to its related benefits such as greater specificity, easy availability and suitability to various research needs.Get Free PDF Sample Copy of the Report (Including Full TOC, List of Tables & Figures) @ https://www.millioninsights.com/industry-reports/research-antibodies-market/request-sampleThe factors that play an important role in the growth of research antibodies market include increasing demand, growing population, increasing urbanization & industrialization, increasing funding for proteomics research & drug discovery, growing R activities & expenditure in the life science industry, increasing demand for personalized medicine & protein therapeutics, technological advancements and stringent government rules & regulations.
The market is widely analyzed based on different regional factors such as gross domestic product (GDP), demographics, acceptance, inflation rate and others.
About UsTransparency Market Research is a global market intelligence company, providing global business information reports and services.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information.
With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.ContactTransparency Market Research, 90 Sate Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: https://www.transparencymarketresearch.com
